# US 2014/0193488 A1 · In Situ Antigen-Generating Cancer Vaccine

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0193488 A1
- Document ID: US20140193488A1
- Status: Published application
- Kind: A1
- Application number: 14/123,615
- Filed: 2012-06-04
- Published: 2014-07-10
- Earliest claimed: 2011-06-03
- Assignees: President and Fellows of Harvard College
- Inventors: Jaeyun Kim; David J. Mooney; Weiwei Aileen Li; Praveen Arany; Or Gadish
- Web page: https://patentgrep.com/patent/US20140193488A1

## CPC

- A61K 39/0011: {Cancer antigens}
- A61K 38/193: {Colony stimulating factors [CSF]}
- A61K 41/0052: {Thermotherapy; Hyperthermia; Magnetic induction; Induction heating therapy}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 35/04: specific for metastasis
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- B82Y 5/00: Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
- A61K 2039/5152: {Tumor cells}
- A61K 2039/5154: {Antigen presenting cells [APCs], e.g. dendritic cells or macrophages}
- A61K 2039/54: {characterised by the route of administration}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- A61K 2039/55505: {Inorganic adjuvants}
- A61K 2039/55511: {Organic adjuvants}
- A61K 2039/55561: {CpG containing adjuvants; Oligonucleotide containing adjuvants}
- A61K 2039/57: {characterised by the type of response, e.g. Th1, Th2}
- A61K 2039/572: {cytotoxic response}
- A61K 2039/70: {Multivalent vaccine}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- B82Y: SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES

## Abstract

The invention provides compositions and methods for utilizing scaffolds in cancer vaccines.

## Claims

### Claim 1

A biopsy-free method for producing a processed tumor antigen in situ comprising administering to a subject diagnosed with a cancer a porous 3-dimensional scaffold, said scaffold comprising a chemoattractant of cancer cells, maintaining said scaffold in situ for a time period sufficient to accumulate a circulating cancer cell to yield a cancer cell-containing scaffold, and contacting said cell-containing scaffold with a cytotoxic or cytolytic element to produce a processed tumor antigen.

### Claim 2 (depends on 1)

The method of claim 1, wherein said cytotoxic element comprises application of external heat, ultrasound, laser radiation, or gamma radiation to said cell-containing scaffold.

### Claim 3 (depends on 2)

The method of claim 2, wherein said laser radiation comprises ultraviolet or near infrared laser radiation.

### Claim 4 (depends on 1)

The method of claim 1, wherein said scaffold further comprises a hyperthermia-inducing composition.

### Claim 5 (depends on 4)

The method of claim 4, wherein said hyperthermia-inducing composition comprises a magnetic nanoparticle or a near infrared (NIR) absorbing nanoparticle.

### Claim 6 (depends on 5)

The method of claim 5, wherein said nanoparticle is magnetic, and wherein said method further comprises contacting said magnetic nanoparticle with an alternately magnetic field to induce local hyperthermia in situ, thereby disrupting said cancer cell and producing a processed tumor antigen.

### Claim 7 (depends on 5)

The method of claim 5, wherein said NIR nanoparticle is selected from the group consisting of a gold nanorod, gold nanoshell, gold nanocage, noble metal nanoparticle, carbon nanotube, carbon nanoparticle, and graphite nanoparticle, and wherein said method further comprises contacting said NIR nanoparticle with NIR radiation to induce local hyperthermia in situ, thereby disrupting said cancer cell and producing a processed tumor antigen.

### Claim 8 (depends on 1)

The method of claim 1, wherein said chemoattractant of cancer cells comprises a chemokine selected from the group consisting of CCL-21, CCL-19, SDF-1, VEGF, and IL-4.

### Claim 9 (depends on 1)

The method of claim 1, wherein said cancer is characterized by circulating tumor cells.

### Claim 10 (depends on 1)

The method of claim 1, wherein said subject is diagnosed with a metastatic cancer condition or a leukemia.

### Claim 11

A tumor antigen-processing device comprising a porous polymer, a chemoattractant for cancer cells, and a cytotoxicity-inducing composition.

### Claim 12 (depends on 11)

The device of claim 11, wherein said cytotoxicity-inducing composition comprises a hyperthermia-inducing particle.

### Claim 13 (depends on 11)

The device of claim 11, wherein said cytotoxicity-inducing composition comprises a gold nanoparticle or a gold nanorod.

### Claim 14 (depends on 11)

The device of claim 11, wherein said device further comprises an immune cell recruitment composition.

### Claim 15 (depends on 14)

The device of claim 14, wherein said immune cell recruitment composition comprises granulocyte macrophage colony-stimulating factor.

### Claim 16 (depends on 14)

The device of claim 14, wherein said chemoattractant, cytotoxicity-inducing composition, and immune cell recruitment composition are interspersed throughout said porous polymer.

### Claim 17 (depends on 14)

The device of claim 14, wherein said porous polymer comprises a first zone comprising said chemoattractant and said cytotoxicity-inducing composition and a second zone comprising said immune cell recruitment composition.

### Claim 18 (depends on 15)

The device of claim 15, wherein said first zone is configured as a core and said second zone is configured as a shell.